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[57] ABSTRACT 
Radiopharmaceutical compositions and methods for 
tumor tomography in mammals are disclosed, wherein 
radioactive gallium and non-radioactive indium are 
injected into said mammals whereby the af?nity of said 
radioactive gallium for non-tumor tissues is decreased, 
resulting in enhanced imaging characteristics. 
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ALTERATION OF GALLIUM BIODISTRIBUTION 
‘ ' USING INDIUM COMPLEXES FOR ENHANCED 
EARLY IMAGING 
BACKGROUND OF THE INVENTION 
1. Field of the Invention ' 
The present invention relates to a diagnostic nuclear 
medicine. More speci?cally, the present invention re 
lates to tumor imaging utilizing radioactive gallium. ' 
2. Description of the Prior Art 
Gallium-67, as the carrier-free citrate,-is used rou 
tinely in clinical medicine in the diagnosis, staging and 
monitoring of several neoplastic disease states (Semin 
Nucl Med 6: 331-334, 1976). Unfortunately, this agent is 
plagued with imaging problems which are related to 
plasma protein binding. Speci?cally, gallium ‘has an 
affinity for blood and soft tissue proteins, and when 
given in very low doses, is extensively bound (J Phar 
macol Exp I71erapeut 168: 193-198, 1973). Gallium also 
has an affinity for tumors (Science 167:289-290, 1970; J 
Nucl Med 10: 103-105, 1969) and abscesses (J Nucl Med 
21: 484-488, 1980). After intravenous administration, ' 
gallium activity in tumors is seen immediately and 
reaches a maximum within eighteen hours (Semin Nucl 
Med 8: 193-203, 1978). Biologic clearing of gallium 
from blood and soft tissue binding sites is a slow pro 
cess, and results in the presence of image obscuring 
activity long after the ideal imaging time. Three major 
consequences of this binding phenomenon are: (a) it is 
necessary to delay imaging procedures for long periods 
of time (48-72 hours) to allow for the clearance of non 
productive radioactivity; (b) the long waiting period 
allows the build-up of image obscuring activity in the 
intestinal tract due to secretion of gallium into the large 
bowel (J Nucl Med 14: 208-214, 1973); and (0) pro 
longed retention of large quantities of 676a in the body 
results in a relatively high radiation dose (J Nucl Med 
12: 755-756, 1973). 
Several reports have described methods or agents 
which attempt to enhance the process of imaging a 
tumor or abscess by shortening the biologic half life of 
carrier-free gallium-67 citrate. Generally, these fall into 
two categories: (a) agents which compete with radioac 
tive gallium for blood and tissue binding sites, thus 
releasing the radioactive metal ion making it available 
for kidney elimination; ‘or (b) complexing‘or chelating ‘ 
agents which compete with blood and tissue binding 
sites for free gallium, forming a complex which is rap 
idly cleared by the kidney. 
The initial work took the ?rst approach and used a 
group (IIB) metal complex (Scandium citrate) as a se 
lective competitive binding agent (South Med J 66: 
1339-1340, 1973; JNucI Med 21: 361-365, 1980). Scan 
dium, by occupying gallium binding sites on blood pro 
teins, prevents the accumulation of gallium on'these 
sites. Scandium appears to have little or no effect upon 
gallium binding in tumors. When used in animal studies, 
where gallium-67 and scandium citrates were injected 
simultaneously, extremely high tumor to blood and 
tumor to tissue ratios were obtained. Unfortunately, 
scandium produces a severe hemolytic anemia when 
administered to man (South Med J 66: 1339-1340, 1973; 
J Nucl Med 21: 361-365, 1980). The use of iron dextran 
in similar fashion to clear gallium from rabbits bearing 
induced abscesses resulted in the clearing of gallium 
with enhanced abscess uptake of gallium (J Nucl Med 
17: 356-358, 1976). This ion, however, has no clinical 
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application due to the large dose of iron required (J 
Nucl Med 21: 421-424, 1980). More recently, it has been 
shown that relatively large doses of non-radioactive 
gallium will decrease blood activity without signi? 
cantly reducing tumor activity (J Nucl Med 20: 656, 
1979; Invest Radiol 14: 482-492, 1979). 
Several investigators have used the second approach, 
employing a chelating agent, desferoxamine, to reduce 
gallium blood activity (J Nucl Med 21: 421-425, 1980; J 
Nucl Med 20: 248-251, 1979; Radiology 131: 775-779, 
1979; Radiolog 130: 241-244, 1979). The resulting gal 
lium desferoxamine complex is eliminated via the kid 
ney at a rate greater than that observed for gallium 
alone. Unfortunately, this clearing agent must be admin 
istered 24 hours after the gallium injection in order to 
minimize loss of tumor activity. 
SUMMARY OF THE INVENTION 
It is, therefore, a primary object of the present inven 
tion to provide improved radiopharmaceutical compo 
sitions and methods for tumor imaging which overcome 
or reduce the above mentioned problems of the prior 
art. 
Carrier-free solutions of gallium-67 citrate were ad 
ministered to normal and tumored rats, and blood levels 
of radioactivity were monitored as a function of time. 
Metal complexes of aluminum, gallium, indium or thal 
lium were administered at times varying from two to six 
hours following the injection of the radiopharmaceuti 
cal. In the cases of indium and gallium, the blood activ 
ity was observed to decrease very rapidly, and a gener 
alized clearing of soft tissue activity was observed. Sim 
ilar studies using imaging techniques, reveal that activ 
ity bound within tumors is obviously affected by the 
addition of moderate doses of carrier gallium. When 
indium citrate was administered two hours after the 
radiopharmaceutical the tumor activity increased sig 
ni?cantly. When carrier-free gallium-67 was adminis 
tered simultaneously with indium citrate, the biodistri 
bution of gallium in rats bearing transplanted tumors 
(lymphoma and hepatoma) was found to be dramati 
cally altered. Two hours after dosing, radioactivity is 
observed in the kidney, bladder, bone and tumor. Other 
areas and tissues were essentially void of activity. This 
rapid clearance of non-productive gallium from diffmse 
soft tissues, blood and organs such as liver, lung and 
spleen demonstrates the potential for use of the gallium 
68 coupled with emission tomography. 
Therefore, in accordance with the present invention, 
it has been discovered that intravenous injection or’ a 
non-radioactive indium complex simultaneously with, 
shortly before or shortly after, the intravenous injection 
of carrier free gal1ium-67(67Ga) or gallium-68(68G:e), 
alters the biodistribution of the radioactive gallium. 
More speci?cally, the indium complex occupies ncm 
tumor gallium receptor sites, and, therefore, the gallium 
will not be retained on these receptor sites to thereby 
obscure the imaging process. In other words, the an 
dium complex has a high affinity for non-tumor galliuun 
receptor sites leaving the gallium free to be bound to tine 
tumor gallium receptor sites. 
It has been shown that indium complexes alter gailii 
um-67 biodistribution in rats bearing transplanted tu 
mors (lymphoma and hepatoma). 
The indium and gallium complexes may be adminns 
tered by injection, with intravenous injection beirng 
preferred. The gallium complexes must be administered 
l 
l 
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ih'carrier-free form with doses in the range of about 0.25 
to 500 ng being preferred. In humans, doses up to 3 mg 
maybe employed. The indium complexes may be ad 
ministered in doses of from about 0.1 to 0.7 mg with 
doses of from about 0.1 to 0.3 mg being preferred. In 
humans doses will be based on blood protein content, 
and may vary up to 50 mg. 
All water-soluble forms of indium such as water-solu' 
ble salts may be used. These water soluble forms include 
water-soluble organic salts, water-soluble inorganic 
salts as well as various water-soluble complexes. Exam 
ples of water-soluble organic salts include indium ci 
trate, indium lactate, indium tartrate, indium phytate, 
and indium phthallate. Examples of water-soluble inor 
ganic salts are indium chloride, indium nitrate, indium 
sulfate, and indium bromide. Another useful form of 
indium is an indiumtransferrin complex. 
All water-soluble forms of gallium suchas water-sol 
uble salts are also useful. Examples of water-soluble 
forms include water-soluble organic salts, water-soluble 
inorganic salts as well as various water-soluble com 
plexes. Examples of water-soluble organic salts include 
gallium citrate, gallium lactate, gallium tartrate, gallium 
phytate and gallium phythallate. Examples of water-sol 
uble inorganic salts include gallium chloride, gallium 
nitrate, gallium sulfate and ‘gallium bromide. An exam 
ple of another form of gallium is a complex of gallium 
and transferrin. 
Radiopharmaceutical compositions may be prepared 
by dissolving the gallium and/or indium complex in any 
acceptable solvent such as water, normal saline, buffer 
normal to the pharmaceutical preparation, and mixtures 
thereof. Normal saline is preferred as a solvent. 
It is preferred to administer the gallium and the in 
dium simultaneously, however, the indium may be ad 
ministered before or after the gallium, preferably within 
2 hours before or after the gallium. ' 
When gallium and indium are administered in accor 
dance with the present invention the following advan 
tages are realized: the time required for image obscuring 
blood and/or soft tissue radioactivity to clear the body, 
enabling one to obtain a clear image of the tumor, is 
reduced; the radiation dose to the patient is reduced by 
increasing the rate at which the radioactive gallium 
clears the body; and the short-lived position emitting 
gallium-68 isotope may be recorded by emission tomo 
graphic imaging equipment to thereby allow viewing of 
the tumor in three dimensions. The radioactive gallium 
may be measured by using external scintigraphic tech 
niques (either photon or positron). 
BRIEF DESCRIPTION OF THE DRAWINGS 
Other objects and advantages of the present invention 
will become apparent from a study of the following 
non-limiting examples and drawings in which 
FIGS. lA-lD are distribution pro?les for carrier~ 
free gallium-67 citrate: 
FIG. 1A is a typical pro?le with no clearing agent 
added; 
FIG. 1B is a typical pro?le observed when carrier 
gallium citrate (3.3 mg/Kg) is given 6 hours (360 min) 
after radiopharmaceutical dosing; 
FIG. 1C is a typical pro?le observed when indium 
chloride (2.1 mg/Kg) is given 6 hours (360 min) after 
radiopharmaceutical dosing; and 
FIG. 1D is a typical pro?le observed when indium 
citratc (2.1 mg/Kg) is given 6 hours (360 min) after 
radiopharmaceutical dosing. 
4 
FIG. 2 is a rectilinear scan of a normal Sprague Daw 
ley rat before and after a clearing dose (3.3 rug/Kg) of 
non-radioactive gallium citrate was administered six 
hours post radiopharmaceutical dosing. 
FIGS. 3A-3C are scans (Union Carbide Cleon model 
720 large ?eld gamma camera) of Buffalo rats bearing 
implanted 5123C hepatomas. - 
FIG. 3A shows the rats two hours'after radiopharma- ' 
ceutical dosing. At this point, the rat on the left re 
ceived carrier gallium citrate (3.3 mg/Kg) and the rat 
on the right received indium citrate (2.1 mg/Kg). 
FIG. 3B shows the rats three hours after radiophar 
maceutical dosing and one hour after injection of the 
clearing agent. 
FIG. 3C shows the rats ?ve hours past radiopharma 
_ ceutical dosing and three hours after the clearing dose. 
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FIGS. 4A-4E are scans (Union Carbide Cleon model 
720 large ?eld gamma camera) of Buffalo rats, bearing 
Morris 5123C hepatoma is injected with a single solu 
tion containing carrier-free gallium-67 citrate and 2.1 
mg/Kg indium citrate. 
FIG. 4A is cumulative over the time period 0 to 10 
mm. 
FIG. 4B is the time period from 10 to 20 min. 
FIG. 4C is the time period from 20 to 30 min. 
FIG. 4D represents the same time period taken one 
hour after the injection. 
FIG. 4E represents the same time period taken two 
hours after the injection. 
EXAMPLES; 
In this study, an external blood-loop technique (IntJ 
of Appl Radiat [sot 29: 189-190, 1978) is used to monitor 
. blood activity of the radiopharmaceutical as a function 
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of time. Relative tissue concentrations are monitored by 
external imaging. 
CHEMICALS AND 
RADIOPHARMACEUTICALS 
All agents, both radioactive and non-radioactive, 
were used as purchased; without further puri?cation. 
Gallium-67 citrate was obtained from Medi-Physics 
(Neosean ®); thallium triacetate and indium chloride 
were obtained from Johnson-Mathey Chemicals Lim 
ited as the nonohydrate; and aluminum lactate was ob 
tained from I.C.N. Pharmaceuticals. 
Gallium citratesolutions were prepared by a method 
similar to that disclosed in J Am Chem -Soc 72: 
3822-3823, 1950. Gallium nitrate (375 mg) was dis 
solved in a minimum volume of boiling concentrated 
hydrochloric acid, citric acid solution (20% w/v, 2.5 
ml) was added thereto, the resulting solution cooled to 
room temperature and neutralized with sodium hydrox 
ide solution (?nal concentration: Ga 15 mg/ml-ZO mg 
citrate/ml, pH 7.4). In a similar manner, indium citrate 
was prepared (?nal concentration: In 6.67 mg/ml-ZO mg 
citrate/ml). Aqueous solutions of aluminum lactate 
(1.42 mg/ml) were obtained by solution in normal sa 
line. All solutions were ?ltered (0.22u millipore ?lter) 
prior to use. 
ANIMAL PREPARATION AND 
RADIOPHARMACEUTICAL DOSING 
For blood clearance studies, male Sprague Dawley 
rats weighing 250—300 grams were used. The animals 
were anesthetized by peritoneal injection of an aqueous 
solution of urethan (l gm/Kg). The right carotid artery 
and left jugular vein were exposed and an external 
4,448,763 
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blood loop (PE-50 tubing; volume=0.l4 ml) was in 
. serted between the vessels. Blood was diverted from the 
artery, through the loop, and back to the animal via the 
vein (Int J of Appl Radiat Isot 29: 189-190, 1978). The 
right external jugular vein was then exposed and cannu 
lated asan injection site. The animal was placed in a 
lead cradle and the blood loop inserted into the shielded 
well of a sodium iodide.thallium crystal. The animal 
received an injection of carrier-free gallium citrate 
(100-120 uCi) via the jugular cannula. Blood activity 
within the loop was continuously monitored as a func 
tion of time using a Packard Model 9012 Multi-channel 
Analyzer/Multi-scaler system (Packard Instrument 
Co., Downersville, 11].). Six hours post injection, the 
animal received a second injection containing one of the 
clearing agents (=72 mmole/Kg). In subsequent experi 
ments, clearing agents were administered two hours 
after or simultaneously with the radioactive dose. 
Initial studies used non-tumored male Sprague Daw 
ley rats weighing between 250 and 300 grams. Subse 
quent studies in tumored rats used male Buffalo rats 
5 
bearing a 5123C hepatoma (The tumor line was initiated ‘ 
from donor animals donated by Drs. R. L. Hayes and B. 25 
Byrd of the Oak Ridge Associated Universities). In all . 
imaging studies, the animals were anesthetized by intra 
peritoneal injection of urethane (l grn/Kg), and the left 
external jugular vein cannulated as a closing site. The 
animals were then positioned under the detection of the 
'y-camera (Union Carbide; CLEON 720 Large Field 
Gamma Camera coupled with a CLEON 110 Image 
Processor) and images were obtained periodically. 
Following a single intravenous injection of carrier 
free gallium-67 citrate in the normal Sprague Dawley 
rat, prepared as described, a blood activity-time curve 
similar to that shown in FIG. 1A is observed. The curve 
is characterized by a rapid distribution phase followed 
by a slower elimination phase. The rapid distribution 
process appears to be complete four to six hours after 
dosing and is in itself multiplastic. There is a very rapid 
component (t; = 12 seconds) which may be due to kid 
ney elimination of the citrate complex. This process 
would become insigni?cant as gallium complexed with 
citrate is transferred to binding sites on blood proteins, 
thus becoming less available for kidney elimination. 
The effect of a relatively large dose of non-radioac 
tive gallium (3.3 mg/Kg) given six hours after the initial 
injection is seen in FIG. 1B. There is a dramatic, rapid 
drop in blood activity (approximately 40% of the blood 
activity is removed). This is followed by a rise in blood 
activity, possibly due to release of 67Ga from less avail 
able gallium stores by an isotopic exchange process. 
The rise in blood activity peaks 1.5 to 2 hours after the 
second injection and subsequent gallium elimination 
parallels that observed when no clearing agent is used. 
When gallium is administered in this manner, the blood 
activity measured eight hours post radiopharmaceutical 
dosing, is approximately 25% less than that observed 
when no clearing agent is given. 
In similar experiments, equimolar quantities of non 
radioactive aluminum, indium, or thallium complexes 
were injected six hours after the carrier-free gallium 
dose. The results of these studies are summarized in 
Table l. 
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TABLE 1 
Relative ability of the group (IIIA) metals to clear 
676a from blood six hours after injection of the radiophannacemi 
cal 
Non 
radioactive % Decrease in. % Increase in Net 
Metals Blood Activity Blood Activity Decrease 
Thallium 0 0 0 
Aluminum 9 3 6 
Gallium 40 15 25 
Indium (Cl) 85 25 60 
There was no change in blood activity following a dose 
of 7.2 mmoles/Kg of thallium triacetate. Aluminum 
lactate caused a reduction of 9% in blood activity fol 
lowed by a 3% rise in activity. The net reduction in 
blood activity was only 6%. Indium chloride proved to 
be the most potent of the clearing agents tested. As was 
the case with non-radioactive gallium, indium chloride 
(FIG. 1C) caused a rapid drop in blood activity (85%) 
followed by an increase which peaked 1.5 to 2 hours 
after the clearing dose was given. The net reduction in 
blood activity was 60%. When indium citrate was used 
in similar fashion, the blood curve was observed to fall 
77% and there was no signi?cant rise in blood activity 
(FIG. 1D). The distributional difference between in 
dium chloride and indium citrate could be explained if 
citrate offered a weak, transient binding for that gallium 
which is displaced from the blood protein binding sites 
now occupied by indium. The gallium citrate complex 
thus formed must be rapidly cleared by the kidney. This 
is the same mechanism suggested above for the rapid 
drop in blood activity seen at early times. In the absence 
of citrate, gallium would seek alternate, non—vascular, 
binding sites (probably surface proteins in tissues) from 
which it would undergo a slower redistribution to 
blood sites vacated as indium undergoes distribution 
processes. 
The two most successful clearing agents, gallium and 
indium citrate, were furher investigated to determine if 
varying the length of time between radiopharmaceuti 
cal dosing and clearing agent dosing altered the results. 
Gallium (3.3 mg/Kg) cleared 78% of the blood activity 
when given at two hours after the radiopharmaceutical. 
This was followed by the characteristic rise in activity 
which resulted in a net clearance of 70%. Indium citrate 
reduced the blood activity by 78% and no subsequent 
rise in activity was observed. ' 
Preliminary imaging studies performed in non 
tumored rats injected with one of the four clearing 
agents six hours post dosing, gave results which gener 
ally paralleled the blood studies. Injections of thallium 
or aluminum yielded no signi?cant redistribution of the 
radioactivity. Injections of non-radioactive gallium or 
indium citrate shifted the radioactivity out of the 
blood/soft tissue regions and into the kidneys and the 
bladder (FIG. 2). 
Clearing studies were performed on tumored rats 
using these agents in dosages suggested as optimal in 
both blood and preliminary imaging studies. Indium 
citrate was dosed at the level of 2.1 mg/Kg, and gallium 
citrate was dosed at 3 mg/Kg and 15 mg/Kg. “'hen 
given six hours after the initial injection, the high dose 
of non-radioactive gallium resulted in obvious redistri 
butions of radioactivity which would have obscured 
chest and abdominal images (i.e. liver, spleen, lung and 
intestine). However, tumor activity was observed to 
decrease. The lower dose of gallium generally has a less 
4,448,763 
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dramatic effect in that a great deal of activity remains in 
the ‘abdomen, particularly in those organs with high 
reticuloendothelial (RE) activity (liver and spleen). 
Also, loss of activity from the tumor is much less. In 
dium is obviously the superior agent, reducing activity 
within the RE rich tissues while not depleting tumor 
activity. However, the effect is not dramatic enough to 
indicate clinical signi?cance. 
When the clearing agent was given two hours post 
radiopharmaceutical dosing, there were signi?cant 
changes in gallium-67 distribution (FIG. 3). Gallium 
citrate (3 mg/Kg) causes some clearing in the upper 
abdomen and in regions of the lower abdomen. There 
was little loss of activity from the tumor region and the 
diagnostic potential of the image was improved. The 
results from use of indium citrate were somewhat more 
dramatic in that the activity is greatly diminished 
throughout the soft tissue regions. Activity in the liver 
spleen-lung region is greatly reduced as it is in the lower 
abdomen. The most signi?cant distributional change, 
however, is the obvious ingrease intumocaetivityf'rhis 
suggests that themecliatiams by which’i‘giallium local 
izes in tumorfrT-Est differ from that directing its localiza 
tion iii other tissues and blood. Further, this suggests 
‘ that indium, like scandium, may allow tumor localiza 
tion of activity while preventing the accumulation of 
activity in blood and tissue when given simultaneously 
with the radiopharmaceutical. To test this hypothesis, 
indium citrate was given with gallium-67 citrate as a 
single solution. As shown in FIG. 4, the distributional 
pattern of gallium-67 is drastically altered. Twenty 
minutes after the mixed dose is given, there is little 
activity outside the kidneys, bladder, tumor and bone. 
After two hours, there is essentially no activity in the 
animal other than in the above mentioned regions. 
Indium citrate, has the ability to successfully compete 
with gallium for blood and soft tissue binding sites, yet 
it does not compete for gallium binding sites in tumor. 
This is a property shared with scandium and iron. It is 
potentially a clinically signi?cant ?nding in that galli 
um-67 citrate, under the distributional in?uence of this 
type agent could be useful for general metastatic 
searches. No longer would the liver-spleen region, a 
common metastatic site, be obscured by activity taken 
up by the RE system. Further, because of the reduced 
time between dosing and imaging, signi?cant abdominal 
secretion does not occur, thus the gut area is free-of 
activity. 
Unlike scandium, indium is not known to rupture red 
blood cells. Toxicity studies following single doses of 
indium citrate indicate that the doses used in this study 
for clearing gallium are in the toxic range (Proc Soc Exp 
Biol Med 29: 1188-1193, 1931; Cancer Chemother Rep 
Part 1 59: 599-6l0 1975;.l1ndustHyg Tax 24; 243-254, 
1942). However, preliminary blood studies in normal 
rats suggest that clearing dose of indium citrate can be 
reduced by as much as an order of magnitude without 
loss of clearing potential. Indium doses in this range 
were not reported to be toxic. 
The use of indium citrate simultaneously with the 
radiopharmaceutical could shorten the dose-to-image 
waiting period from day to minutes, making possible the 
use of the shorter lived isotope gallium-68 (t5=68 min 
Utes) for tumor imaging. This isotope, while biologi 
cally identical to gallium-67, has the added advantage of 
positron emission, introducing the potential for emission 
tomggllipily and all the inherent advantages of three 
dimcnslnll?i imaging. 
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The invention being thus described, it will be obvious 
that the same way be varied in many ways. Such varia 
tions are not to__ be regarded as a departure from the 
spirit and scope of the invention, and all such modi?ca 
tions as would be obvious to.one skilled in the art are 
intended to be included within the scope of the follow 
ing claims. . 
What is claimed is: 
1. A radiopharmaceutical composition, comprising: 
radioactive gallium, non-radioactive indium and a 
pharmaceutically acceptable carrier or diluent. 
2. A radiopharmaceutical composition according to 
claim 1, wherein said radioactive: gallium is gallium 67 
or gallium 68. 
3. A radiopharmaceutical composition according to 
claim 1', in the form of an injectable solution. 
4. A radiopharmaceutical composition according to 
claim 3, wherein said gallium and indium are present in 
the form of water-soluble salts or complexes. 
5. A radiopharmaceutical composition according to 
claim 4, wherein the concentration of said indium in 
said injectable solution is between 0.3 mg/ml and 2.1 
mg/ml. 
6. A radiopharmaceutical composition according to 
claim 5, wherein the said gallium in said injectable solu 
tion is in carrier-free form. 
v7. A radiopharmaceutical diagnostic kit, comprising: 
an effective tumor imaging amount of water-soluble 
radioactive gallium; and ' 
an effective tumor imaging improving amount of 
water-soluble non-radioactive indium. 
8. A method for detecting tumors in mammals com 
prising: ' 
administering to said mammals an effective tumor 
imaging amount of radioactive gallium and an ef 
fective tumor imaging improving amount of non 
radioactive indium and measuring the biodistribu 
tion of said radioactive gallium using external scin 
tigraphic techniques. 
9. A method according to claim 8, wherein said gal 
lium is administered by injection. 
10. A method according to claim 9, wherein said 
indium is injected in an amount of between 0.1 mg/Kg 
and 2.] mg/Kg. 
11. A method according to claim 9, wherein said 
gallium is injected in carrier-free quantities. 
12. A radiopharmaceutical composition according to 
claim 1, wherein said composition includes a water-sol 
uble organic salt of radioactive gallium. 
13. A radiopharmaceutical composition according to 
claim 1, wherein said composition includes a water-sol 
uble organic salt of non-radioactive indium. 
14. A radiopharmaceutical composition according to 
claim 1, wherein said composition includes radioactive 
gallium citrate. 
15. A radiopharmaceutical composition according to 
‘ claim 1, wherein said composition includes non-radioac 
60 
tive indium citrate. 
16. A pharmaceutical composition according to claim 
1, wherein said composition includes a water-soluble 
inorganic salt of radioactive gallium. 
17. A pharmaceutical composition according to claim 
1, wherein said composition includes a water-soluble 
inorganic salt of non-radioactive indium. 
18. A radiopharmaceutical composition according to 
claim 1, wherein said composition includes an organic 
salt of radioactive gallium selected from the group con 
4,448,763 
sisting of gallium citrate, gallium lactate, gallium tar 
_ trate, gallium phytate and gallium phythallatc. 
19. A radiopharmaceutical composition according to 
claim 1, wherein said composition includes an inorganic 
salt of radioactive gallium selected from the group con 
sisting of gallium chloride, gallium nitrate, gallium sul 
fate and gallium bromide. 
20. A'radiopharmaceutical composition according to 
claim 1, wherein said composition includes a complex of 
radioactive gallium and transferrin. 
21. A radiopharmaceutical composition according to 
claim 1, wherein said composition includes an organic 
salt of non-radioactive indium selected from the group 
consisting of indium citrate, indium lactate, indium tar 
trate, indium phytate and indium phthallate. 15 
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' 22. A radiopharmaceuticall composition according to 
claim 1, wherein said composition includes an inorganic 
salt of non-radioactive indium selected from the group 
consisting of indium chloride, indium nitrate, indium 
sulfate and indium bromide. 
23. A radiopharmaccutical composition according to 
claim 1, wherein said composition includes a non~radi~ 
oactive indium-transferrin complex. 
24. A radiopharmaceutical composition, consisting 
essentially of: 
an effective tumor imaging . amount of radioactive 
gallium, an effective tumor imaging improving 
amount of non-radioactive indium; and. 
a pharmaceutically acceptable carrier or diluent. 
i i t i l 
